For instance, the mTOR inhibitor RAD001 enhanced anti-leukemic effects of sunitinib in AML cell lines and primary samples [36] and concomitant blockade by sunitinib and the MEK/ERK inhibitor AZD6244 induced synergistic inhibitory effects in FLT3-mutated AML cell lines and primary samples [37]. This evidence concerns the gene MTOR and acute myeloid leukemia.